UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Annals of oncology, 2018-02, Vol.29 (2), p.405-417

2018

Volltextzugriff (PDF)

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Acta oncologica, 2017-01, Vol.56 (1), p.88-92

2017

Volltextzugriff (PDF)

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of oncology, 2014-06, Vol.25 (6), p.1128-1136

2014

Volltextzugriff (PDF)

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Annals of oncology, 2014-03, Vol.25 (3), p.719-724

2014

Volltextzugriff (PDF)

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Annals of oncology, 2018-08, Vol.29 (8), p.1777-1783

2018

Volltextzugriff (PDF)

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Breast cancer research and treatment, 2018, Vol.167 (1), p.123-131

2018

Volltextzugriff (PDF)

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

BMC cancer, 2021-03, Vol.21 (1), p.323-9, Article 323

2021

Volltextzugriff (PDF)

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

Gynecologic oncology, 2016-07, Vol.142 (1), p.89-94

2016

Volltextzugriff (PDF)

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

European journal of cancer (1990), 2015-07, Vol.51 (10), p.1312-1320

2015

Volltextzugriff (PDF)

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials

European journal of cancer (1990), 2015-11, Vol.51 (17), p.2615-2623

2015

Volltextzugriff (PDF)

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-07, Vol.30 (7), p.448-454

2018

Volltextzugriff (PDF)

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study

European journal of cancer (1990), 2018-05, Vol.94, p.187-198

2018

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-05, Vol.26 (5), p.865-872

2015

Volltextzugriff (PDF)

Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)

Pediatric blood & cancer, 2017-08, Vol.64 (8), p.n/a

2017

Volltextzugriff (PDF)

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy

Gynecologic oncology, 2016-07, Vol.142 (1), p.95-101

2016

Volltextzugriff (PDF)

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

The pharmacogenomics journal, 2015-02, Vol.15 (1), p.63-68

2015

Volltextzugriff (PDF)

The impact of a misspecified random-effects distribution on the estimation and the performance of inferential procedures in generalized linear mixed models

Statistics in medicine, 2008-07, Vol.27 (16), p.3125-3144

2008

Volltextzugriff (PDF)

13 From warehouse to new RECIST criteria?

European journal of cancer (1990), 2012-11, Vol.48, p.8-8

2012

Volltextzugriff (PDF)

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

European journal of cancer (1990), 2014-12, Vol.50 (18), p.3178-3186

2014

Volltextzugriff (PDF)

Reply to Verlingue, Koscielny and Ferté

European journal of cancer (1990), 2014-11, Vol.50 (16), p.2889-2891

2014

Volltextzugriff (PDF)

211 Phase III Trial (EORTC 10801) Comparing Breast-conserving Therapy with Radical Mastectomy – Twenty Year Follow-up Results

European journal of cancer (1990), 2012-03, Vol.48, p.S104-S105

2012

Volltextzugriff (PDF)

OC-0134 LOCAL EXCISION WITH OR WITHOUT RADIOTHERAPY IN DUCTAL CARCINOMA IN SITU: TREATMENT AND PROGNOSIS AFTER A RECURRENCE

Radiotherapy and oncology, 2012-05, Vol.103, p.S52-S53

2012

Volltextzugriff (PDF)

493 Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial

European journal of cancer (1990), 2012-03, Vol.48, p.S190-S190

2012

Volltextzugriff (PDF)

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

Annals of oncology, 2014-12, Vol.25 (12), p.2425-2432

2014

Volltextzugriff (PDF)

1 – 25 von 172

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(162)

Publikationsform

Artikel
(171)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(96)
Oncology
(83)
Humans
(70)
Female
(48)
Adult
(39)
Middle Aged
(38)
Male
(35)
Aged
(29)
Hematology, Oncology And Palliative Medicine
(29)
Tumors
(27)
Prognosis
(25)
Sarcoma
(24)
Chemotherapy
(22)
Sarcoma - Drug Therapy
(21)
Patients
(20)
Treatment Outcome
(20)
Metastasis
(19)
Disease-Free Survival
(16)
Metastases
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072

A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial

Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials

European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy

Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Investigating the heterogeneity of alkylating agents’ efficacy and toxicity between sexes: A systematic review and meta‐analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)

Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy

Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial

The impact of a misspecified random-effects distribution on the estimation and the performance of inferential procedures in generalized linear mixed models

13 From warehouse to new RECIST criteria?

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

Reply to Verlingue, Koscielny and Ferté

211 Phase III Trial (EORTC 10801) Comparing Breast-conserving Therapy with Radical Mastectomy – Twenty Year Follow-up Results

OC-0134 LOCAL EXCISION WITH OR WITHOUT RADIOTHERAPY IN DUCTAL CARCINOMA IN SITU: TREATMENT AND PROGNOSIS AFTER A RECURRENCE

493 Sentinel Node Identification Rate and Further Nodal Involvement in Patients with Multifocal Breast Cancer in the EORTC 10981-22023 AMAROS Trial

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials

Suchergebnisse filtern